Ebru Derici EKER, Nilgun Solak TEKİN, Sevim Karakas CELİK, Nefise OZLEN SAHİN

The relationship between VITiligo and endothelial nitric oxide GLU298ASP and intron 4 VNTR polymorphism

Vitiligo is a chronic autoimmune depigmentation disease characterized by loss of melanocyte function in the epidermis. The pathogenesis of vitiligo remains unclear. In recent years, there is increasing evidence that some gene polymorphisms are risk factors for this disease. In this study, we designed to investigate whether there is a relationship between endothelial nitric oxide synthase (eNOS) gene Glu298Asp (G894T) and intron 4 VNTR polymorphisms and vitiligo. The study included 87 patients diagnosed with vitiligo and 96 healthy volunteers in the dermatology clinic of Bülent Ecevit University Medical Faculty. Polymerase chain reaction and enzyme restriction (PCR-RFLP) methods were used to detect Glu298Asp and intron 4 VNTR polymorphism. There was no significant difference between the groups in terms of GG, GT, and TT genotype distributions and allele frequencies in terms of eNOS Glu298Asp gene polymorphism (p=0.076). There was a significant difference between eNOS intron 4 VNTR polymorphisms in terms of genotype distribution and allele frequency (p=0.004). It was found that BB genotype increased the risk of disease 3.6 times compared to AB genotype. Although the pathogenesis is not known, genetic and immunological factors cooperate a role in the cause of vitiligo. Our study is thought to make an essential contribution to the literature in terms of being the first study on this subject.

PDF

___

1. Aksungur VL, Tüzün Y, Gürer MA, et al. Dermatoloji. 3rd edition. Nobel Tıp K, İstanbul, 2008.

2. Arıcan Ö. Vitiligoda etyoloji, patogenez ve klinik. Kartal Eğitim ve Araştırma Hastanesi Derg. 2004;15:55-60.

3. Ongenae K, Geel NV, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003;16:90-100.

4. Zhang XJ, Chen JJ, Liu JB. The genetic concept of vitiligo. J Dermatol Sci. 2005;39:137-46.

5. Zhang XJ, Liu JB, Gui JP, et al. Characteristics of genetic epidemilogy and genetic models for vitiligo. J Am Acad Dermatol. 2004;51:383-90.

6. Karıncaoğlu Y, Doğan G. Vitiligo. Türkiye Klinikleri J Med Sci. 2001;21:200-9.

7. Kopera D. Historical aspects and definition of vitiligo. Clin Dermatol. 1997;15:841-3.

8. Millington GWM, Levell NJ. Vitiligo: the historical curse of depigmentation. Int J Dermatol. 2007;46:990-5.

9. Safarinejad MR, Safarinejad S, Shafiei N, et al. Effects of the T-786C, G894T, and intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer. Urol Oncol. 2013;31:1132-40.

10. Liu S, Gu T, Fu J, et al. Quantum dots-hyperbranched polyether hybrid nanospheres towards delivery and real-time detection of nitric oxide. Mater Sci Eng C Mater Biol Appl. 2014;45:37-44.

11. Salvucci O, Carsana M, Bersani I, et al. Antiapoptotic role of endogenous nitric oxide in human melanoma cells. Cancer Res. 2001;61:318-26.

12. Glueck CJ, Munjal J, Khan A, et al. Endothelial nitric oxide synthase T-786C mutation, a reversible etiology of Prinzmetal’s angina oectoris. Am J Cardiol. 2010;105:792-6.

13. Carr A, Frei B. The role of natural antioxidants in preserving the biological activity of endothelium derived nitric oxide. Free Radical Biology Medicine. 2000;28:1806-14.

14. Geller DA, Billiar TR. Molecular biology of nitric oxide synthases. Cancer Metastasis Rev. 1998;17:7-23.

15. Romero-Graillet C, Aberdam E, Biagioli N, et al. Ultraviolet B radiation acts through the nitric oxide and cGMP signal transduction pathway to stimulate melanogenesis in human melanocytes. J Biol Chem. 1996;271:28052-6.

16. Ekmekcioglu S, Ellerhorst J, Prieto VG, et al. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer. 2006;119:861-6.

17. Iuga AO, Qureshi AA, Lerner EA. Nitric oxide is toxic to melanocytes in vitro. Pigment Cell Res. 2004;17:302-6.

18. Ivanova K, van den Wijngaard R, Gerzer R, et al. Non-lesional vitiliginous melanocytes are not characterized by an increased proneness to nitric oxide-induced apoptosis. Exp Dermatol. 2005;14: 445-53.

19. Wolf K, Goldsmith LA, Katz SI, et al. Fitzpatrick’s Dermatology In General Medicine. 7th edition. New York: Mc Graw- Hill Book Company, 2008.

20. Braun-Falco O, Plewing G, Wolff HH, et al. Dermatology. 2nd edition. Berlin: Springer Verlag, 2000.

21. Kemp EH, Waterman EA, Weetman AP. Immunological pathomechanisms in vitiligo. Exp Rev Mol Med. 2001;23:3:1-22.

22. Almasi-Nasrabadi M, Amoli MM, Robati RM, et al. CDH1 and DDR1 common variants confer risk to vitiligo and autoimmune comorbidities. Gene. 2019;5:700:17-22.

23. Delmas V, Larue L. Molecular and cellular basis of depigmentation in vitiligo patients. Exp Dermatol. 2019;28:662-6.

24. Xu W, Wang X. Detection of melanocyte lineage-specific genes in vitiligo lesions. Exp Ther Med. 2019;17:4485-91.

25. Tarlé, RG, Silva de Castro CC, do Nascimento LM, et al. Polymorphism of the E-cadherin gene CDH1 is associated with susceptibility to vitiligo. Exp Dermatol. 2015;24:300-2.

26. Onan D, Yorulmaz A, Ezgü FS, et al. The role of IFIH1 gene rs1990760 and rs2111485 single-nucleotide polymorphisms in generalized vitiligo predisposition. Turk J Med Sci. 2019;49:206-11.

27. Zhang JZ, Wang M, Ding Y, et al. Vitamin D receptor gene polymorphism, serum 25-hydroxyvitamin D levels, and risk of vitiligo: A meta-analysis. Medicine (Baltimore). 2018;97:e11506.

28. Tuna A, Ozturk G, Gerceker TB, et al. Superoxide Dismutase 1 and 2 Gene Polymorphism in Turkish Vitiligo Patients. Balkan J Med Genet. 2017;20:67-74.